<DOC>
	<DOC>NCT00094367</DOC>
	<brief_summary>This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and 150 mg of lamivudine administered as separate tablets twice-daily.</brief_summary>
	<brief_title>A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)</brief_title>
	<detailed_description>A phase IIIB randomized, open-label, multicenter, parallel-arm study to evaluate the short-term safety and tolerability of the abacavir/lamivudine fixed-dose combination tablet administered once-daily or the separate abacavir and lamivudine tablets administered twice-daily, as part of a three or four-drug regimen, in antiretroviral naive HIV-1 infected subjects.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Have HIV1 infection. Had not received any prior HIV treatment for more than 14 days. At least 1000 copies of HIV1 RNA. Willing to provide signed informed consent. Enrolled in other investigational drug studies. Female subjects who are pregnant or breastfeeding. History of allergy or hypersensitivity to abacavir or lamivudine. Certain medical conditions that would make subjects ineligible.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>1592U89</keyword>
	<keyword>GR109714</keyword>
	<keyword>abacavir</keyword>
	<keyword>lamivudine</keyword>
	<keyword>fixed-dose combination</keyword>
	<keyword>once-daily</keyword>
	<keyword>twice-daily</keyword>
	<keyword>HIV infection</keyword>
	<keyword>naive</keyword>
</DOC>